First-line treatment for RCC varies among risk rate (good, intermediate, and poor risk calculated by the tumor stage, size, grade, and necrosis (SSIGN) score method [4]) of patients, but the standardized guideline suggests a targeted therapy cocktail with tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, and mammalian target of rapamycin (mTOR) inhibitors [5]. This evidence concerns the gene MTOR and renal cell adenocarcinoma.